Open Access

Simvastatin improves cerebrovascular injury caused by ischemia‑reperfusion through NF‑κB‑mediated apoptosis via MyD88/TRIF signaling

  • Authors:
    • Zhiying Chen
    • Yuanyuan Xiang
    • Bing Bao
    • Xiangbin Wu
    • Zhongbin Xia
    • Jianyou You
    • Hongbing Nie
  • View Affiliations

  • Published online on: July 30, 2018     https://doi.org/10.3892/mmr.2018.9337
  • Pages: 3177-3184
  • Copyright: © Chen et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Cerebrovascular injury is the most prevalent human cerebrovascular disease and frequently results in ischemic stroke. Simvastatin may be a potential therapeutic agent for the treatment of patients with cerebrovascular injury. The present study aimed to investigate the efficacy of and the potential mechanisms regulated by simvastatin in a rat model of ischemia‑reperfusion (I/R)‑induced cerebrovascular injury. Cerebrovascular injury model rats were established and were subsequently treated with simvastatin or a vehicle control following I/R injury. Cell damage, neurological functions and neuronal apoptosis were examined, as well as the nuclear factor (NF)‑κB‑mediated myeloid differentiation primary response protein 88 (MyD88)/toll‑interleukin‑1 receptor domain‑containing adapter molecule 1 (TRIF) signaling pathway following simvastatin treatment. The results of the present study demonstrated that simvastatin treatment led to a reduction in cell damage, improvement of neurological functions and decreased neuronal apoptosis compared with vehicle‑treated I/R model rats, 14 days post‑treatment. In addition, simvastatin treatment reduced cerebral water content and blood‑brain barrier disruption in cerebrovascular injury induced by I/R. The results also revealed that simvastatin treatment inhibited neuronal apoptosis via the NF‑κB‑mediated MyD88/TRIF signaling pathway. In conclusion, simvastatin treatment may reduce I/R‑induced neuronal apoptosis via inhibition of the NF‑κB‑mediated MyD88/TRIF signaling pathway.
View Figures
View References

Related Articles

Journal Cover

September-2018
Volume 18 Issue 3

Print ISSN: 1791-2997
Online ISSN:1791-3004

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Chen Z, Xiang Y, Bao B, Wu X, Xia Z, You J and Nie H: Simvastatin improves cerebrovascular injury caused by ischemia‑reperfusion through NF‑κB‑mediated apoptosis via MyD88/TRIF signaling. Mol Med Rep 18: 3177-3184, 2018.
APA
Chen, Z., Xiang, Y., Bao, B., Wu, X., Xia, Z., You , J., & Nie, H. (2018). Simvastatin improves cerebrovascular injury caused by ischemia‑reperfusion through NF‑κB‑mediated apoptosis via MyD88/TRIF signaling. Molecular Medicine Reports, 18, 3177-3184. https://doi.org/10.3892/mmr.2018.9337
MLA
Chen, Z., Xiang, Y., Bao, B., Wu, X., Xia, Z., You , J., Nie, H."Simvastatin improves cerebrovascular injury caused by ischemia‑reperfusion through NF‑κB‑mediated apoptosis via MyD88/TRIF signaling". Molecular Medicine Reports 18.3 (2018): 3177-3184.
Chicago
Chen, Z., Xiang, Y., Bao, B., Wu, X., Xia, Z., You , J., Nie, H."Simvastatin improves cerebrovascular injury caused by ischemia‑reperfusion through NF‑κB‑mediated apoptosis via MyD88/TRIF signaling". Molecular Medicine Reports 18, no. 3 (2018): 3177-3184. https://doi.org/10.3892/mmr.2018.9337